Review



genome wide association data ( p-values)  (Broad Institute Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Broad Institute Inc genome wide association data ( p-values)
    We show that new information on the functional basis of the observed associations can be inferred from the biochemical properties of the affected metabolites. Moreover, both genes were previously reported to be associated with common clinical phenotypes, FADS1 in an extent which would not attract immediate attention for follow-up in a <t>genome-wide</t> context. Since several genes and pathways are involved in the development of a clinical endpoint, the IP focuses on one pathway (e.g., cholesterol or a given metabotype) which is already known to be involved in the clinical endpoint (e.g. coronary artery disease (CAD)). It is much easier to identify the genes which are associated with the IP since the associations of genetic variation with the IP is much stronger than with the clinical endpoint. Environmental factors interact at different levels with the IPs and thereby add to the variability in the system. The closer the IP is related to the genetic polymorphism, the stronger the <t>association</t> is expected to be. In our case the association reflects enzymatic activity of FADS1 and LIPC which results in very strong effect sizes of the genetically determined metabotype.
    Genome Wide Association Data ( P Values), supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/genome+wide+association+data+%28+p-values%29/pmc02581785-309-0-20?v=Broad+Institute+Inc
    Average 90 stars, based on 1 article reviews
    genome wide association data ( p-values) - by Bioz Stars, 2026-08
    90/100 stars

    Images

    1) Product Images from "Genetics Meets Metabolomics: A Genome-Wide Association Study of Metabolite Profiles in Human Serum"

    Article Title: Genetics Meets Metabolomics: A Genome-Wide Association Study of Metabolite Profiles in Human Serum

    Journal: PLoS Genetics

    doi: 10.1371/journal.pgen.1000282

    We show that new information on the functional basis of the observed associations can be inferred from the biochemical properties of the affected metabolites. Moreover, both genes were previously reported to be associated with common clinical phenotypes, FADS1 in an extent which would not attract immediate attention for follow-up in a genome-wide context. Since several genes and pathways are involved in the development of a clinical endpoint, the IP focuses on one pathway (e.g., cholesterol or a given metabotype) which is already known to be involved in the clinical endpoint (e.g. coronary artery disease (CAD)). It is much easier to identify the genes which are associated with the IP since the associations of genetic variation with the IP is much stronger than with the clinical endpoint. Environmental factors interact at different levels with the IPs and thereby add to the variability in the system. The closer the IP is related to the genetic polymorphism, the stronger the association is expected to be. In our case the association reflects enzymatic activity of FADS1 and LIPC which results in very strong effect sizes of the genetically determined metabotype.
    Figure Legend Snippet: We show that new information on the functional basis of the observed associations can be inferred from the biochemical properties of the affected metabolites. Moreover, both genes were previously reported to be associated with common clinical phenotypes, FADS1 in an extent which would not attract immediate attention for follow-up in a genome-wide context. Since several genes and pathways are involved in the development of a clinical endpoint, the IP focuses on one pathway (e.g., cholesterol or a given metabotype) which is already known to be involved in the clinical endpoint (e.g. coronary artery disease (CAD)). It is much easier to identify the genes which are associated with the IP since the associations of genetic variation with the IP is much stronger than with the clinical endpoint. Environmental factors interact at different levels with the IPs and thereby add to the variability in the system. The closer the IP is related to the genetic polymorphism, the stronger the association is expected to be. In our case the association reflects enzymatic activity of FADS1 and LIPC which results in very strong effect sizes of the genetically determined metabotype.

    Techniques Used: Functional Assay, Genome Wide, Activity Assay



    Similar Products

    genome wide association data ( p-values)  (Broad Institute Inc)
    90
    Broad Institute Inc genome wide association data ( p-values)
    We show that new information on the functional basis of the observed associations can be inferred from the biochemical properties of the affected metabolites. Moreover, both genes were previously reported to be associated with common clinical phenotypes, FADS1 in an extent which would not attract immediate attention for follow-up in a <t>genome-wide</t> context. Since several genes and pathways are involved in the development of a clinical endpoint, the IP focuses on one pathway (e.g., cholesterol or a given metabotype) which is already known to be involved in the clinical endpoint (e.g. coronary artery disease (CAD)). It is much easier to identify the genes which are associated with the IP since the associations of genetic variation with the IP is much stronger than with the clinical endpoint. Environmental factors interact at different levels with the IPs and thereby add to the variability in the system. The closer the IP is related to the genetic polymorphism, the stronger the <t>association</t> is expected to be. In our case the association reflects enzymatic activity of FADS1 and LIPC which results in very strong effect sizes of the genetically determined metabotype.
    Genome Wide Association Data ( P Values), supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/genome+wide+association+data+%28+p-values%29/pmc02581785-309-0-20?v=Broad+Institute+Inc
    Average 90 stars, based on 1 article reviews
    genome wide association data ( p-values) - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    We show that new information on the functional basis of the observed associations can be inferred from the biochemical properties of the affected metabolites. Moreover, both genes were previously reported to be associated with common clinical phenotypes, FADS1 in an extent which would not attract immediate attention for follow-up in a genome-wide context. Since several genes and pathways are involved in the development of a clinical endpoint, the IP focuses on one pathway (e.g., cholesterol or a given metabotype) which is already known to be involved in the clinical endpoint (e.g. coronary artery disease (CAD)). It is much easier to identify the genes which are associated with the IP since the associations of genetic variation with the IP is much stronger than with the clinical endpoint. Environmental factors interact at different levels with the IPs and thereby add to the variability in the system. The closer the IP is related to the genetic polymorphism, the stronger the association is expected to be. In our case the association reflects enzymatic activity of FADS1 and LIPC which results in very strong effect sizes of the genetically determined metabotype.

    Journal: PLoS Genetics

    Article Title: Genetics Meets Metabolomics: A Genome-Wide Association Study of Metabolite Profiles in Human Serum

    doi: 10.1371/journal.pgen.1000282

    Figure Lengend Snippet: We show that new information on the functional basis of the observed associations can be inferred from the biochemical properties of the affected metabolites. Moreover, both genes were previously reported to be associated with common clinical phenotypes, FADS1 in an extent which would not attract immediate attention for follow-up in a genome-wide context. Since several genes and pathways are involved in the development of a clinical endpoint, the IP focuses on one pathway (e.g., cholesterol or a given metabotype) which is already known to be involved in the clinical endpoint (e.g. coronary artery disease (CAD)). It is much easier to identify the genes which are associated with the IP since the associations of genetic variation with the IP is much stronger than with the clinical endpoint. Environmental factors interact at different levels with the IPs and thereby add to the variability in the system. The closer the IP is related to the genetic polymorphism, the stronger the association is expected to be. In our case the association reflects enzymatic activity of FADS1 and LIPC which results in very strong effect sizes of the genetically determined metabotype.

    Article Snippet: Genome wide association data ( p -values) from three recent GWA studies was downloaded on 21 February 2008 from http://www.broad.mit.edu/diabetes/scandinavs/metatraits.html (Broad Institute ) and http://www.sph.umich.edu/csg/abecasis/public/lipids/ (University of Michigan ) and on 14 March 2008 from http://www.wtccc.org.uk/info/summary_stats.shtml (Wellcome Trust Case Control Consortium ).

    Techniques: Functional Assay, Genome Wide, Activity Assay